- Home
- SBMT vs ARMP Comparison
SBMT vs ARMP Comparison
Compare SBMT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBMT | ARMP |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 295.5M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SBMT | ARMP |
|---|---|---|
| Price | $6.45 | $4.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 185.6K | ★ 193.0K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $2.14 |
| 52 Week High | $8.98 | $14.98 |
Technical Indicators
Market Signals| Indicator | SBMT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 28.60 |
| Support Level | $5.75 | N/A |
| Resistance Level | $8.00 | $7.67 |
| Average True Range (ATR) | 0.77 | 0.67 |
| MACD | -0.06 | -0.13 |
| Stochastic Oscillator | 22.29 | 1.08 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.